Synthetic peptide may regenerate brain tissue in stroke victims

"This successful experiment holds promise for treating clot-induced strokes in humans," says study lead author Daniel C. Morris, M.D., senior staff physician in the Department of Emergency Medicine at Henry Ford Hospital. "Neurorestorative therapy is the next frontier in the treatment of stroke."

He will present the findings June 3 at the Annual Meeting of the Society for Academic Emergency Medicine in Phoenix.

Dr. Morris explains that the researchers added the synthetic peptide Thymosin beta 4 to a group of drug treatments -- including statins -- used for neurorestorative therapy to activate repair mechanisms which mimic cellular changes that occur in the early stages of brain development.

This research follows an earlier study, reported by the same team in March, which found that Thymosin beta 4 improved neurological function after stroke in adult rats by increasing the formation of protective myelin around nerve fibers in brain cells.

These experiments conclude that the peptide repairs and regenerates stroke-injured brain tissue.

The results of the first study also were similar to other research using the peptide to regenerate damaged heart, corneal tissue and wound repair.

In the latest study, adult rats were dosed with Thymosin beta 4 one day after they were subjected to a blockage in the cerebral artery, then given four more doses, once every three days. Rats treated only with saline were used as a control group.

After eight weeks, the Thymosin beta 4 group showed significant overall improvement compared to the control group.

The researchers concluded that the peptide improved blood vessel density as well as promoted a certain type of immature brain cells called oligodendrocyte progenitor cells to differentiate into mature oligodendrocytes, which produces myelin to protect axons in nerve cells.

In addition to Dr. Morris, the Henry Ford research team included Michael Chopp, Ph.D.; Li Zhang, M.D.; and Zheng Gang Zhang.

Thymosin beta 4 is produced by RegeneRx Biopharmaceuticals, Inc.

The study was funded by the National Institutes of Health.